SB-269970

• Description :

  SB-269970 is a potent, selective and brain-penetrant 5-HT7 receptor antagonist with a pKi of 8.3. SB-269970 exhibits >50-fold selectivity against other 5-HT receptors[1][2].

• UNSPSC :

  12352005

• Target :

  5-HT Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/SB-269970.html

• Purity :

  98.78

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  OC1=CC=CC(S(=O)(N2[C@@H](CCN3CCC(C)CC3)CCC2)=O)=C1

• Molecular Formula :

  C18H28N2O3S

• Molecular Weight :

  352.49

• References & Citations :

  [1]Hagan JJ, et al. Characterization of SB-269970-A, a selective 5-HT (7) receptor antagonist. Br J Pharmacol. 2000 Jun;130 (3) :539-48.|[2]Roberts C, et al. The effect of SB-269970, a 5-HT (7) receptor antagonist, on 5-HT release from serotonergic terminals and cell bodies. Br J Pharmacol. 2001 Apr;132 (7) :1574-80.|[3]Nikiforuk A, et al. Effects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats. PLoS One. 2013 Jun 11;8 (6) :e66695.|[4]Monti JM, et al. The serotonin 5-HT7 receptor agonist LP-44 microinjected into the dorsal raphe nucleus suppresses REM sleep in the rat. Behav Brain Res. 2008 Aug 22;191 (2) :184-9.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  5-HT7 Receptor; MUC3

• Citation 01 :

  J Physiol. 2025 Sep;603 (17) :4723-4745.|Protein Cell. 2019 Mar;10 (3) :178-195.|Authorea. September 19, 2022.|Cancer Lett. 2024 Aug 1:217150.|Int J Biol Sci. 2024 Aug 19;20 (11) :4476-4495.|Neuron. 2025 Jun 18;113 (12) :1983-1997.e7.

• CAS Number :

  [201038-74-6]